Aktuellt
SENASTE
Redeye comments on Scandion Oncology’s Q3 2023 report, one day after the company announced intriguing final data from CORIST part 2. Final CORIST part 2 data indicated elongated survival versus cited historical controls. We believe reported data is promising. However, they require confirmation in a controlled randomised trial. We do some housekeeping in our model and finetune our estimates and valuation.
LÄS MER
